The objective of this study was to examine associations of symptoms with physical and mental health-related quality of life (HRQOL) in patients with colorectal cancer (CRC) and in patients with lung cancer. METHODS: Patients with newly diagnosed CRC (n 5 3040) or lung cancer (n 5 2297) who were participating in the Cancer Care Outcomes Research and Surveillance Consortium study completed surveys on general HRQOL and symptoms. HRQOL was measured by using physical component summary (PCS) and mental component summary (MCS) scores on the Medical Outcomes Study 12-item short-form heath survey. Nonspecific cancer symptoms were measured using items from the European Organization for Research and Treatment of Cancer core quality-oflife questionnaire. Cancer type-specific modules developed by the European Organization for Research and Treatment of Cancer were used to assess CRC-specific and lung cancer-specific symptoms. For both cancer types, linear regression models that were controlled for demographic and clinical information were used to examine correlations of nonspecific and cancer-specific symptoms with PCS and MCS scores. RESULTS: PCS scores for patients with CRC and lung cancer were below the general population norm of 50 (43 and 37, respectively), and MCS scores were at the population norm. For the CRC sample, in the model that included both symptom indices, an increase in nonspecific symptoms was more strongly associated with lower PCS and MCS scores than an increase in CRCspecific symptoms (PCS, standardized coefficient 
INTRODUCTION
Lung cancer and colorectal cancer (CRC) are the leading non-sex related cancers among men and women, and it is estimated that they will account for greater than 360,000 incident cases in 2014. 1 Health-related quality of life (HRQOL) serves as an important outcome in cancer clinical trials and is an increasingly important outcome for evaluating quality of care. For patients with lung cancer and CRC, especially those diagnosed with advanced disease, information about HRQOL can contribute to better palliative and supportive care interventions from the time of diagnosis. 2, 3 Because lung cancer is often diagnosed at an advanced stage, assessment of HRQOL can facilitate the evaluation of treatment practices and the effect of symptoms on patient comfort. 4 Introducing palliative care management for symptoms early in the cancer process is an emphasis of the recently released Institute of Medicine report on delivering high-quality cancer care and is a goal of organizations like the American Society of Clinical Oncology and the National Comprehensive Cancer Network. [5] [6] [7] To support the implementation of these recommendations, more information is needed on the specific symptoms associated with HRQOL, especially close to the time of diagnosis. Walling and colleagues 8 reported symptom prevalence using data from the Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium study of patients with newly diagnosed lung cancer and CRC. 9 Almost all patients (93%) in that study reported at least some symptoms, and over half of patients reported moderate to severe symptoms. 8 Patients with CRC are burdened by disease-specific symptoms, such as stoma-related or defecation problems. 10 Patients with lung cancer also have disease-specific symptoms, such as cough and dyspnea. 11 Both patients with CRC and those with lung cancer also may experience nonspecific cancerrelated symptoms, such as nausea, vomiting, or trouble sleeping. The extent to which cancer symptoms are associated with general HRQOL has had more limited evaluation. 12 In addition, much of the information on the correlation of symptoms with HRQOL in newly diagnosed patients comes from clinical trials or small samples derived from single institutions, limiting the generalizability of findings. 13, 14 Thus, we chose to address these gaps using a population-based patient sample from CanCORS, hypothesizing that the mitigation of symptom burden early in the disease and treatment trajectory could potentially affect long-term HRQOL. Knowing which symptoms contribute to poorer HRQOL can help prioritize the planning of palliative interventions that have been called for across the cancer care continuum. 5, 6 For this study, our objectives were to provide information regarding HRQOL in patients with newly diagnosed lung cancer and CRC and to assess the extent to which cancer type-specific symptoms and nonspecific cancer symptoms contribute to poorer HRQOL.
MATERIALS AND METHODS

Data
Data were obtained from CanCORS, which is a cohort study of patients with lung cancer and CRC that was established by the National Cancer Institute in 2001. 9 CanCORS recruited patients from 5 geographically defined regions, 5 integrated health care delivery systems in the Cancer Research Network, and 15 veterans' hospitals. Recruitment for the CanCORS study was described in detail by Ayanian et al in 2004 . 9 Between 2003 and 2005, patients were surveyed at an average of 4 months after diagnosis. Participants were surveyed about their cancer, treatment, symptoms, HRQOL, and health care quality. 15 Clinical information was abstracted from medical records. Abbreviated and surrogate versions of the surveys were available for those who were unable to complete the full version or who had died at the time of the survey.
Study Sample
The CanCORS cohort included 4723 patients with CRC and 5013 patients with lung cancer. For the current study, we included the 3040 CRC participants and 2297 lung cancer participants who had completed the full survey at baseline, because the questions of interest were only asked in the full survey (CanCORS data, version 12). The study protocol was approved by institutional review boards of all participating research groups.
Measures
Patient-reported measures
The primary dependent variables were scores on the Medical Outcomes Study 12-item short form health survey (SF-12) physical component summary (PCS) and mental component summary (MCS). 16 The PCS and MCS are weighted combinations of items that measure physical functioning, role limitations caused by physical health problems, bodily pain, general health, mental health, role limitations caused by emotional problems, social functioning, and vitality. On these measures, higher scores indicate better health. The US general population mean score (6 standard deviation) for the PCS and MCS is 50 6 10.
CRC-specific and lung cancer-specific symptom items were selected subscales from the 38-item, CRC-specific European Organization for Research and Treatment of Cancer (EORTC) quality-of-life questionnaire (EORTC QLQ-CR-38) 17 and the 13-item, lung cancerspecific EORTC QLQ-LC13 18 questionnaire. For CRC, symptom items included problems caring for stoma, skin irritation around the stoma, and feeling embarrassed by the stoma (for stoma patients only) and frequency of bowel movements, unintentional release of stools, or blood in stools (defecation symptoms for nonstoma patients). Lung cancer-specific symptoms included coughing, coughing blood, shortness of breath at rest, shortness of breath, shortness of breath while walking, shortness of breath when climbing stairs, sore mouth or tongue, trouble swallowing, and pain or tingling in hands or feet. Because of conceptual overlap with SF-12 items, we excluded "shortness of breath when climbing stairs" and "pain or tingling in hands or feet" from the lung cancer-specific symptom index score.
Nonspecific cancer symptoms were measured using items from the 30-item core EORTC quality-of-life questionnaire (EORTC QLQ-C30) 19 symptom scale that were asked of patients in both the lung cancer sample and the CRC sample. Items included trouble sleeping, lack of appetite, nausea, vomiting, constipation, diarrhea, and shortness of breath. The shortness-of-breath item was included only for patients in the CRC sample, because the specific shortness-of-breath items were included in the cancer-specific index for lung cancer.
Participants indicated how much they had experienced each symptom in the past 4 weeks using a categorical rating scale ranging from "not at all" to "quite a bit." The summed scores for all symptom scales were transformed linearly to scale from 0 to a possible score of 100. 20 Higher scores indicated more symptoms. ). Standardized coefficients (b) are reported, and effect sizes were used to compare differences in the standardized coefficients for the symptom indices. 21 Statistical analyses were conducted using SAS version 9.3 (SAS Institute Inc, Cary, NC). 22 Table 1 indicates that most patients in the CRC and lung cancer samples were aged >55 years (74% and 85%, respectively), white (66% and 68%, respectively), and men (55% and 51%, respectively). Almost all patients in the CRC sample underwent surgery (93%), and half of patients in the lung cancer sample underwent surgery (50%). Approximately 15% and 27% of patients in the CRC and lung cancer samples, respectively, had stage IV disease.
RESULTS
Characteristics of Survey Respondents
HRQOL and Symptoms
The mean PCS score was 43 for the patients with CRC and 37 for the patients with lung cancer ( Table 2 ). The mean MCS score was 51 for the patients with CRC and 50 for the patients with lung cancer. For patients in the CRC sample, internal consistency reliability (Cronbach a) of the stoma and defecation scales was .60 and .71, respectively. For patients in the lung cancer sample, internal consistency reliability of the lung cancer-specific scale was .60. For the nonspecific symptom scales, internal consistency reliability was .66 for the CRC sample and .65 for the lung cancer sample.
The product-moment correlation between the nonspecific and cancer type-specific symptom scales was 0.51 for the CRC sample and 0.43 for the lung cancer sample. Among patients in both the CRC sample and the lung cancer sample, trouble sleeping was the most frequently reported nonspecific cancer symptom (Supporting Table 1 ; see online supporting information). The prevalence of symptoms ranged from 11% (blood in stool) to 64% (frequent bowel movements) among patients in the CRC sample and from 7% (coughing blood) to 82% (cough) among patients in the lung cancer sample. Table 3 indicates that model 2 (nonspecific symptoms only; adjusted R 2 5 0.29) explained more variance in the PCS score than model 1 (cancer type-specific symptoms only; adjusted R 2 5 0.19) for patients with CRC. Demographic and clinical variables accounted for 12% of the total variance in each model. In addition, the nonspecific symptoms had a significantly greater association with an overall decrease in the PCS score compared with the cancer type-specific symptoms in model 3 (b 5 20.41 vs 20.09; effect size, 0.32). Older age (models 1 and 3); being a woman; lower education; receiving chemotherapy (model 1), surgery, or radiation; higher disease stage at diagnosis; and having more comorbidities were associated with lower PCS scores. Unstandardized coefficients are provided in Supporting Tables 2 and 3 (see online supporting information).
Multivariable Models Examining Associations With HRQOL
CRC
For the MCS score, model 1 (cancer type-specific symptoms only; adjusted R 2 5 0.11) explained more variance than model 2 (nonspecific symptoms only; adjusted R 2 5 0.07). Demographic and clinical variables accounted for 6% of the total variance in each model. Nonspecific symptoms had significantly greater associations with the MCS score in model 3 (b 5 20.38 vs 20.08; effect size, 0.30). Older age and higher education were associated with significantly higher MCS scores. In model 1, being a woman was negatively associated with the MCS score, and being married was positively associated with the MCS score. Chemotherapy was significantly associated with poorer MCS scores in model 1, and radiation was significant in model 2. Table 4 indicates that model 1 (adjusted R 2 5 0.24) accounted for more variance in the PCS score than model 2 (adjusted R 2 5 0.18). Demographic and clinical variables accounted for 8% of the total variance in each model. In model 3, the association of the negative relation of the cancer type-specific symptoms was marginally higher than that of the nonspecific cancer symptoms (b 5 20.34 vs 20.20; effect size, 0.14). African American patients had significantly higher PCS scores than white patients. Lower education (model 1 and 3), undergoing surgery (model 1 only) and receiving radiation, higher disease stage at diagnosis, and comorbidities were associated with lower PCS scores.
Lung cancer
In contrast to the PCS score, the association between the nonspecific symptom index and the MCS score was patients with CRC and those with lung cancer reported similarly high levels of their respective cancer type-specific symptoms, lung cancer symptoms had a stronger association with physical HRQOL among patients with lung cancer than the stoma/defecation symptoms had for patients with CRC. Although both groups of CanCORS participants had mental HRQOL scores comparable to those reported in the general population, their symptoms also contributed to mental HRQOL: nonspecific symptoms were more strongly associated with mental HRQOL than cancer-specific symptoms for both the CRC sample and the lung cancer sample.
The physical and mental HRQOL scores for both the CRC sample and the lung cancer sample were similar to findings from previous studies. 23, 24 The prevalence of some symptoms, however, was higher in our study. For example, patients in our CRC sample were more likely to report constipation (33% vs 22%) and diarrhea (43% vs 32%) than the sample studied by Wilson et al. 23 This comparison may seem to contradict findings on the association between increasing symptoms and worse HRQOL. However, even in the study by Wilson et al, SF-12 PCS and MCS scores were significantly worse only for the patients who had severe symptoms compared with those who had mild or moderate symptoms. 23 Among patients with lung cancer, Fleming and colleagues reported HRQOL similar to that observed in our lung cancer sample. 24 We note that 92% of our patients with lung cancer experienced at least 1 cough or dyspnea symptom, which is slightly higher than what was reported in a systematic review of lung cancer patients (range, 50%-87%). 11 Collectively, these results suggest that, although there is a strong association between symptoms and HRQOL, the assessment of HRQOL alone using generic summary scores may miss bothersome symptoms that warrant clinical attention.
Both the cancer type-specific symptoms and the nonspecific cancer symptoms were associated with worse self-reported physical and mental health. In our CRC sample, nonspecific symptoms were more strongly associated with HRQOL than cancer-specific symptoms. Although cancer type-specific symptoms were significantly associated with lower physical and mental HRQOL after controlling for nonspecific symptoms, the lower strength of the association may be because of the few stoma patients in our sample (12%). Previous studies have suggested that stoma patients have worse symptoms and poorer HRQOL than nonstoma patients. 23 For example, stoma-related problems may negatively affect normal activities, such as work duties, likely impacting emotional and social functioning. 25 In contrast to patients with CRC, patients with lung cancer reported cancer type-specific symptoms more frequently than nonspecific cancer symptoms. The later stage at diagnosis may partially explain this finding. Cough/dyspnea symptoms were more strongly associated with physical HRQOL than nonspecific symptoms, supporting cancer type-specific symptom measures to identify and treat problem areas to improve physical HRQOL. 26 The stronger association between nonspecific symptoms and mental HRQOL may be related to the high frequency of reporting trouble sleeping, which has been associated with increased mental distress. 27 Overall, other potential risk factors for worse physical and mental HRQOL were being a woman, low education, higher disease stage at diagnosis, and receipt of chemotherapy and radiation. Older age was associated with lower physical HRQOL but with higher mental HRQOL. In addition, we observed negative associations between comorbidities and physical HRQOL. Comorbidities are also an indicator for introducing palliative care according to National Comprehensive Cancer Network guidelines. 7 Even after accounting for demographic, clinical, and symptom factors, in both our CRC sample and our lung cancer sample, the total variance explained was relatively low (range, 7%-30%). This may be due to the fact that HRQOL is a multidimensional construct and can be affected by other psychosocial or psychological factors that were not included in our model, for example, coping strategies, stress levels, and social support and family life. Second, our measure of comorbidity was only a count of comorbidity, not a measure of severity. Finally, we did not include measures of quality of care received.
Our study provides population-based estimates of symptoms and HRQOL in patients with cancer near the time of diagnosis and enriches the findings from previous studies that were based on small, nonrepresentative samples 28 or on multiple, collapsed cancer types. 29 Our findings describe the symptoms experienced across all stages of disease early during cancer care: palliative care strategies traditionally reserved for end-stage disease may alleviate these same symptoms in earlier stage patients. 30 In post hoc analyses, we compared the regression results stratified by localized and metastatic disease. The association of nonspecific and cancer type-specific symptoms with PCS and MCS scores remained the same across localized and metastatic subgroups both for patients with CRC and for patients with lung cancer. The symptom associations with HRQOL also were similar compared with the findings from the nonstratified sample. This further demonstrates that that symptoms are a burden on HRQOL even in patients with localized disease, and patients are in need of supportive care strategies that can address symptoms with the objective of improving their HRQOL
The current study has several limitations. The majority of patients (>97%) have health insurance, which may limit the generalizability of our findings. However, CanCORS incorporates several health care delivery systems and geographically distinct sites. 31 Second, patients who were unable to complete the full version of the survey were not included in our analysis; therefore, our sample was healthier than the full cohort. Third, data for this study were obtained between 2003 and 2005; however, treatments for these cancers have not changed substantially. Information from this representative cohort is important for addressing the issues in the recent Institute of Medicine report on high-quality cancer care. 5 In addition, we were unable to discern whether symptoms were treatment side-effects, caused by the disease itself, or the result of other comorbidities. Finally, we do not present longitudinal changes in HRQOL.
The current study demonstrates that both patients with CRC and those with lung cancer experience symptoms that are negatively associated with quality of life, especially physical HRQOL. Symptom and HRQOL assessment is important for obtaining a comprehensive understanding of patient needs at diagnosis, regardless of disease stage. By generating evidence on the correlation between symptom burden and HRQOL in a populationbased cancer sample, our findings support the positions of the Institute of Medicine and American Society of Clinical Oncology that symptom relief and supportive care strategies should be implemented early in the cancer care process and across all stages. 
